IDH1 and IDH2 mutations in pediatric acute leukemia

A. K. Andersson, D. W. Miller, J. A. Lynch, A. S. Lemoff, Z. Cai, S. B. Pounds, I. Radtke, B. Yan, J. D. Schuetz, J. E. Rubnitz, R. C. Ribeiro, S. C. Raimondi, J. Zhang, C. G. Mullighan, S. A. Shurtleff, B. A. Schulman, J. R. Downing

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

To investigate the frequency of isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) mutations in pediatric acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL), we sequenced these genes in diagnostic samples from 515 patients (227 AMLs and 288 ALLs). Somatic IDH1/IDH2 mutations were rare in ALL (N=1), but were more common in AML, occurring in 3.5% (IDH1 N=3 and IDH2 N=5), with the frequency higher in AMLs with a normal karyotype (9.8%). The identified IDH1 mutations occurred in codon 132 resulting in replacement of arginine with either cysteine (N=3) or histidine (N=1). By contrast, mutations in IDH2 did not affect the homologous residue but instead altered codon 140, resulting in replacement of arginine with either glutamine (N=4) or tryptophan (N=1). Structural modeling of IDH2 suggested that codon 140 mutations disrupt the enzyme's ability to bind its substrate isocitrate. Accordingly, recombinant IDH2 R140Q/W were unable to carry out the decarboxylation of isocitrate to α-ketoglutarate (α-KG), but instead gained the neomorphic activity to reduce α-KG to R(-)-2-hydroxyglutarete (2-HG). Analysis of primary leukemic blasts confirmed high levels of 2-HG in AMLs with IDH1/IDH2 mutations. Interestingly, 3/5 AMLs with IDH2 mutations had FLT3-activating mutations, raising the possibility that these mutations cooperate in leukemogenesis.

Original languageEnglish (US)
Pages (from-to)1570-1577
Number of pages8
JournalLeukemia
Volume25
Issue number10
DOIs
StatePublished - Oct 2011

Fingerprint

Isocitrate Dehydrogenase
Leukemia
Pediatrics
Mutation
Codon
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Arginine
Decarboxylation
Glutamine
Karyotype
Histidine
Tryptophan
Cysteine

Keywords

  • acute lymphoid leukemia
  • acute myeloid leukemia
  • IDH1
  • IDH2
  • isocitrate dehydrogenase
  • pediatric AML

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Andersson, A. K., Miller, D. W., Lynch, J. A., Lemoff, A. S., Cai, Z., Pounds, S. B., ... Downing, J. R. (2011). IDH1 and IDH2 mutations in pediatric acute leukemia. Leukemia, 25(10), 1570-1577. https://doi.org/10.1038/leu.2011.133

IDH1 and IDH2 mutations in pediatric acute leukemia. / Andersson, A. K.; Miller, D. W.; Lynch, J. A.; Lemoff, A. S.; Cai, Z.; Pounds, S. B.; Radtke, I.; Yan, B.; Schuetz, J. D.; Rubnitz, J. E.; Ribeiro, R. C.; Raimondi, S. C.; Zhang, J.; Mullighan, C. G.; Shurtleff, S. A.; Schulman, B. A.; Downing, J. R.

In: Leukemia, Vol. 25, No. 10, 10.2011, p. 1570-1577.

Research output: Contribution to journalArticle

Andersson, AK, Miller, DW, Lynch, JA, Lemoff, AS, Cai, Z, Pounds, SB, Radtke, I, Yan, B, Schuetz, JD, Rubnitz, JE, Ribeiro, RC, Raimondi, SC, Zhang, J, Mullighan, CG, Shurtleff, SA, Schulman, BA & Downing, JR 2011, 'IDH1 and IDH2 mutations in pediatric acute leukemia', Leukemia, vol. 25, no. 10, pp. 1570-1577. https://doi.org/10.1038/leu.2011.133
Andersson AK, Miller DW, Lynch JA, Lemoff AS, Cai Z, Pounds SB et al. IDH1 and IDH2 mutations in pediatric acute leukemia. Leukemia. 2011 Oct;25(10):1570-1577. https://doi.org/10.1038/leu.2011.133
Andersson, A. K. ; Miller, D. W. ; Lynch, J. A. ; Lemoff, A. S. ; Cai, Z. ; Pounds, S. B. ; Radtke, I. ; Yan, B. ; Schuetz, J. D. ; Rubnitz, J. E. ; Ribeiro, R. C. ; Raimondi, S. C. ; Zhang, J. ; Mullighan, C. G. ; Shurtleff, S. A. ; Schulman, B. A. ; Downing, J. R. / IDH1 and IDH2 mutations in pediatric acute leukemia. In: Leukemia. 2011 ; Vol. 25, No. 10. pp. 1570-1577.
@article{0ba454b56c864ba9bbe4320d4bc4f1d5,
title = "IDH1 and IDH2 mutations in pediatric acute leukemia",
abstract = "To investigate the frequency of isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) mutations in pediatric acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL), we sequenced these genes in diagnostic samples from 515 patients (227 AMLs and 288 ALLs). Somatic IDH1/IDH2 mutations were rare in ALL (N=1), but were more common in AML, occurring in 3.5{\%} (IDH1 N=3 and IDH2 N=5), with the frequency higher in AMLs with a normal karyotype (9.8{\%}). The identified IDH1 mutations occurred in codon 132 resulting in replacement of arginine with either cysteine (N=3) or histidine (N=1). By contrast, mutations in IDH2 did not affect the homologous residue but instead altered codon 140, resulting in replacement of arginine with either glutamine (N=4) or tryptophan (N=1). Structural modeling of IDH2 suggested that codon 140 mutations disrupt the enzyme's ability to bind its substrate isocitrate. Accordingly, recombinant IDH2 R140Q/W were unable to carry out the decarboxylation of isocitrate to α-ketoglutarate (α-KG), but instead gained the neomorphic activity to reduce α-KG to R(-)-2-hydroxyglutarete (2-HG). Analysis of primary leukemic blasts confirmed high levels of 2-HG in AMLs with IDH1/IDH2 mutations. Interestingly, 3/5 AMLs with IDH2 mutations had FLT3-activating mutations, raising the possibility that these mutations cooperate in leukemogenesis.",
keywords = "acute lymphoid leukemia, acute myeloid leukemia, IDH1, IDH2, isocitrate dehydrogenase, pediatric AML",
author = "Andersson, {A. K.} and Miller, {D. W.} and Lynch, {J. A.} and Lemoff, {A. S.} and Z. Cai and Pounds, {S. B.} and I. Radtke and B. Yan and Schuetz, {J. D.} and Rubnitz, {J. E.} and Ribeiro, {R. C.} and Raimondi, {S. C.} and J. Zhang and Mullighan, {C. G.} and Shurtleff, {S. A.} and Schulman, {B. A.} and Downing, {J. R.}",
year = "2011",
month = "10",
doi = "10.1038/leu.2011.133",
language = "English (US)",
volume = "25",
pages = "1570--1577",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - IDH1 and IDH2 mutations in pediatric acute leukemia

AU - Andersson, A. K.

AU - Miller, D. W.

AU - Lynch, J. A.

AU - Lemoff, A. S.

AU - Cai, Z.

AU - Pounds, S. B.

AU - Radtke, I.

AU - Yan, B.

AU - Schuetz, J. D.

AU - Rubnitz, J. E.

AU - Ribeiro, R. C.

AU - Raimondi, S. C.

AU - Zhang, J.

AU - Mullighan, C. G.

AU - Shurtleff, S. A.

AU - Schulman, B. A.

AU - Downing, J. R.

PY - 2011/10

Y1 - 2011/10

N2 - To investigate the frequency of isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) mutations in pediatric acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL), we sequenced these genes in diagnostic samples from 515 patients (227 AMLs and 288 ALLs). Somatic IDH1/IDH2 mutations were rare in ALL (N=1), but were more common in AML, occurring in 3.5% (IDH1 N=3 and IDH2 N=5), with the frequency higher in AMLs with a normal karyotype (9.8%). The identified IDH1 mutations occurred in codon 132 resulting in replacement of arginine with either cysteine (N=3) or histidine (N=1). By contrast, mutations in IDH2 did not affect the homologous residue but instead altered codon 140, resulting in replacement of arginine with either glutamine (N=4) or tryptophan (N=1). Structural modeling of IDH2 suggested that codon 140 mutations disrupt the enzyme's ability to bind its substrate isocitrate. Accordingly, recombinant IDH2 R140Q/W were unable to carry out the decarboxylation of isocitrate to α-ketoglutarate (α-KG), but instead gained the neomorphic activity to reduce α-KG to R(-)-2-hydroxyglutarete (2-HG). Analysis of primary leukemic blasts confirmed high levels of 2-HG in AMLs with IDH1/IDH2 mutations. Interestingly, 3/5 AMLs with IDH2 mutations had FLT3-activating mutations, raising the possibility that these mutations cooperate in leukemogenesis.

AB - To investigate the frequency of isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) mutations in pediatric acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL), we sequenced these genes in diagnostic samples from 515 patients (227 AMLs and 288 ALLs). Somatic IDH1/IDH2 mutations were rare in ALL (N=1), but were more common in AML, occurring in 3.5% (IDH1 N=3 and IDH2 N=5), with the frequency higher in AMLs with a normal karyotype (9.8%). The identified IDH1 mutations occurred in codon 132 resulting in replacement of arginine with either cysteine (N=3) or histidine (N=1). By contrast, mutations in IDH2 did not affect the homologous residue but instead altered codon 140, resulting in replacement of arginine with either glutamine (N=4) or tryptophan (N=1). Structural modeling of IDH2 suggested that codon 140 mutations disrupt the enzyme's ability to bind its substrate isocitrate. Accordingly, recombinant IDH2 R140Q/W were unable to carry out the decarboxylation of isocitrate to α-ketoglutarate (α-KG), but instead gained the neomorphic activity to reduce α-KG to R(-)-2-hydroxyglutarete (2-HG). Analysis of primary leukemic blasts confirmed high levels of 2-HG in AMLs with IDH1/IDH2 mutations. Interestingly, 3/5 AMLs with IDH2 mutations had FLT3-activating mutations, raising the possibility that these mutations cooperate in leukemogenesis.

KW - acute lymphoid leukemia

KW - acute myeloid leukemia

KW - IDH1

KW - IDH2

KW - isocitrate dehydrogenase

KW - pediatric AML

UR - http://www.scopus.com/inward/record.url?scp=80054035931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054035931&partnerID=8YFLogxK

U2 - 10.1038/leu.2011.133

DO - 10.1038/leu.2011.133

M3 - Article

VL - 25

SP - 1570

EP - 1577

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 10

ER -